Latest Updates of Key Players in the U.S. Small Molecule innovator API CDMO Market
Company Updates
| Company | Headquarters | Latest Update |
| Lonza Group Ltd. | Switzerland | Lonza Group AG has quietly become one of the most influential biomanufacturing solutions on the planet. |
| Thermo Fisher Scientific Inc. | United States | In July 2025, Thermo Fisher Scientific Inc. expanded its strategic collaboration with Sanofi to allow additional U.S. drug product production. |
| Catalent, Inc. | Florida | Catalent delivers end-to-end pharma services as a trusted CDMO, advancing drug development and manufacturing worldwide |
| Cambrex Corporation | United States | In October 2025, Cambrex announced a $120 million spending to expand its U.S. operations, addressing increased demand for API development and production, and accelerating the company’s leadership role in the fast-growing peptide therapeutics. |
| Recipharm AB | Sweden | Recipharm expands its industrial operations to meet demanding FDA requirements. |
| CordenPharma International | Switzerland | CordenPharma's Small Molecule platform provides large-scale advanced intermediates and APIs to final drug products for your GMP outsourcing supply chain. |
Value Chain Analysis
R&D:
- Major R&D processes involve a structured, many-step, and compliance-based strategy that transforms a medicinal chemistry discovery route into a safe, scalable, and economical commercial production process.
- Key Players: CSL Vifor and Daiichi Sankyo Company, Ltd.
Manufacturing Processes:
- Major manufacturing processes involved in clinical trial drug sourcing are a series of complex, cGMP-compliant processes to transform raw chemical materials into the active pharmaceutical ingredients (APIs) for novel drugs.
- Key Players: Pharmacosmos A/S, and Fresenius Kabi AG
Patient Services:
- Key services involve an early-stage advancement to commercialization, focusing on improving bioavailability, enhancing adherence, and ensuring a safe, consistent supply of medication.
- Key Players: Sanofi
Market Growth
The U.S. small molecule innovator API CDMO market size was estimated at USD 9.37 billion in 2025 and is predicted to increase from USD 9.94 billion in 2026 to approximately USD 16.85 billion by 2035, expanding at a CAGR of 6.04% from 2026 to 2035.
Recent Developments in the U.S. Small Molecule Innovator API CDMO Market
- In January 2026, Siegfried signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience.
- In January 2026, Agno Pharma, a contract development and manufacturing organization (CDMO) specializing in small-molecule active pharmaceutical ingredients (APIs) and critical GMP intermediates, announced the acquisition of Actylis Eugene, the legacy Cascade Chemistry business based in Eugene, Oregon.
- In November 2025, HRV Global Life Sciences (HRV Pharma), India's first integrated Virtual API and Pharmtech company, announced a unique, comprehensive, multi-year Contract Development & Manufacturing (CDMO) partnership with MetroChem API Pvt. Ltd., one of India's leading API development and manufacturing companies.
Everything you need to monitor the market, organized and accessible - Access the Dashboard
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
